Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.

Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof wherein a seal coat is not present between the substrate and the saxagliptin layer.

The present invention provides saxagliptin bisulphate saxagliptin acetate saxagliptin oxalate saxagliptin bicarbonate and saxagliptin carbonate their polymorphic forms processes for their preparation and pharmaceutical compositions thereof.

Physical crystal structures of a compound of the formula (I): are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1) and hydrochloric acid salt Pattern P-5 preferably in substantially pure form and other forms as described herein pharmaceutical compositions containing structures of compound I o...

The present invention relates to stable pharmaceutical compositions comprising DPP4 inhibitor. More particularly, the present invention relates to stable pharmaceutical compositions comprising saxagliptin or a pharmaceutically acceptable salt thereof.

Improved processes for preparing saxagliptin or its salt and intermediates thereof are provided.

The present invention provides saxagliptin bisulphate, saxagliptin acetate, saxagliptin oxalate, saxagliptin bicarbonate, and saxagliptin carbonate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof.

The present invention provides a novel amorphous solid dispersion of saxagliptin in combination with a pharmaceutically acceptable carrier process for its preparation and pharmaceutical compositions comprising it. In a preferred embodiment the process for the preparation of amorphous solid dispersion of saxagliptin in combination with a pharmaceutically acceptable carrier comprises: preparing a solution comprising a mixture of saxagliptin and one or more pharmaceutically acceptable carriers sele...

601408 Disclosed are 5-aryl-isothiazol-3-ol 1-oxide derivatives / 1-oxo-5-aryl-isothiazolidin-3-one derivatives as represented by the general formula (I), where n is an integer of 1

Provided are novel processes for the preparation of Saxagliptin and novel intermediates employed in the process for preparing Saxagliptin.